Drug
Rly 2608
Rly 2608: highest development phase Phase 2, developed by Relay Therapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Relay Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| RLY-2608 NCT06789913 | Phase 2 | PIK3CA-Related Overgrowth Spectrum (PROS) |
| RLY-2608 NCT05216432 | Phase 1 | PIK3CA Mutation |
Latest
No recent events.
Follow Rly 2608 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.